Literature DB >> 24295662

Treatment approaches to primary tracheal cancer.

Dirk Behringer1, Stefan Könemann2, Erich Hecker3.   

Abstract

A patient identified with tracheal cancer benefits most from evaluation by an experienced center and an extensive effort to assess the possibility of a complete surgical resection as the most efficient treatment option for cure. Localized, nonoperable disease may still be controlled by combined modality using chemotherapy and concurrent radiation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Combined modality; Radiotherapy; Tracheal cancer; Treatment

Mesh:

Substances:

Year:  2014        PMID: 24295662     DOI: 10.1016/j.thorsurg.2013.10.002

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  5 in total

1.  Epidemiology and treatment trends for primary tracheal squamous cell carcinoma.

Authors:  Mohammad K Hararah; William A Stokes; Ayman Oweida; Tejas Patil; Arya Amini; Julie Goddard; Daniel W Bowles; Sana D Karam
Journal:  Laryngoscope       Date:  2019-04-12       Impact factor: 3.325

2.  Competing risk analysis of primary tracheal carcinoma based on SEER database.

Authors:  HongXiang Gao; Xuan He; JianFei Du; SanHu Yang; Yang Wang; JunWei Zhang; ChenNian Zhao
Journal:  Cancer Manag Res       Date:  2019-01-24       Impact factor: 3.989

3.  Pulmonary actinomycosis and tracheal squamous cell carcinoma: A rare simultaneous presentation of both in a single patient.

Authors:  Yazan Zayed; Danielle Osterholzer; Emily Armstrong; Qazi Azher; Ghassan Bachuwa
Journal:  Respir Med Case Rep       Date:  2019-05-17

4.  Radiation Therapy for Tracheobronchial Metastases from Head and Neck Squamous Cell Carcinoma.

Authors:  Nikhil Yegya-Raman; Sachin R Jhawar; Salma K Jabbour; Sabiha Hussain; Sung Kim
Journal:  Cureus       Date:  2018-08-15

5.  Clinical features and prognosis analysis of 57 patients with primary tracheal tumors.

Authors:  Mao Jiang; Qunjuan Lei; Xin Lv; Lijun Zou; Jingjing Liu; Jie Meng
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.